Ascendiant Capital Markets Cuts BIOLASE (NASDAQ:BIOL) Price Target to $14.00

BIOLASE (NASDAQ:BIOLGet Rating) had its price objective decreased by Ascendiant Capital Markets to $14.00 in a research report released on Wednesday morning, Stock Target Advisor reports.

BIOL has been the topic of a number of other research reports. Maxim Group reduced their target price on BIOLASE from $10.00 to $5.00 in a report on Friday, November 11th. StockNews.com started coverage on BIOLASE in a report on Wednesday, November 9th. They issued a sell rating on the stock. Finally, Benchmark reduced their target price on BIOLASE to $7.00 in a report on Wednesday.

BIOLASE Price Performance

BIOL stock opened at $1.68 on Wednesday. BIOLASE has a 52-week low of $1.40 and a 52-week high of $13.83. The stock’s fifty day simple moving average is $2.21 and its 200-day simple moving average is $3.65. The company has a quick ratio of 1.99, a current ratio of 2.46 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $12.01 million, a price-to-earnings ratio of -0.47 and a beta of 1.45.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Perkins Capital Management Inc. lifted its stake in shares of BIOLASE by 11.6% during the third quarter. Perkins Capital Management Inc. now owns 132,070 shares of the medical technology company’s stock worth $321,000 after purchasing an additional 13,770 shares in the last quarter. State Street Corp lifted its stake in shares of BIOLASE by 4.5% during the first quarter. State Street Corp now owns 436,076 shares of the medical technology company’s stock worth $154,000 after purchasing an additional 18,682 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of BIOLASE during the second quarter worth about $118,000. Essex Investment Management Co. LLC lifted its stake in shares of BIOLASE by 2.5% during the first quarter. Essex Investment Management Co. LLC now owns 1,621,992 shares of the medical technology company’s stock worth $573,000 after purchasing an additional 39,281 shares in the last quarter. Finally, Armistice Capital LLC lifted its stake in shares of BIOLASE by 8.2% during the third quarter. Armistice Capital LLC now owns 699,000 shares of the medical technology company’s stock worth $1,699,000 after purchasing an additional 52,887 shares in the last quarter. Institutional investors and hedge funds own 21.21% of the company’s stock.

BIOLASE Company Profile

(Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

See Also

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.